Adenosine monophosphate-activated protein kinase agonist

Patent metadata

Field	Value
Publication number	US-10793527-B2
Application number	US-201716331388-A
Country	US
Kind code	B2
Filing date	Sep 6, 2017
Priority date	Sep 7, 2016
Publication date	Oct 6, 2020
Grant date	Oct 6, 2020

Abstract

The present invention discloses a compound of the formula (I), which acts as an agonist of adenosine monophosphate-activated protein kinase, which induce phosphorylation and activation of AMPKα, thereby further regulating downstream signaling pathways, inhibiting growth and proliferation of liver cancer cells and breast cancer cells, and also inducing apoptosis of adipocytes. Therefore, the compound provided by the present invention can be utilised for treatment and preparation of pharmaceutical composition for cancer, and lipid metabolism-related diseases or syndromes mediated by AMPK.

First claim

The invention claimed is:

1. A compound of the formula (I):

or a pharmaceutically acceptable salt thereof, wherein
R 1 is an unsubstituted or substituted aromatic group; R 3 is selected from the group consisting of a phenyl urea group substituted by —CF 3 , —Cl, —OCF 3 , —CH 3 , —C 2 H 5 , —COOMe, —COOH, or a combination thereof and a substituted

Ar is an unsubstituted or substituted phenylene group.

2. The compound, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein the unsubstituted or substituted phenylene group is

and R 2 is a hydrogen atom, a halide, or an alkyl group.

3. The compound, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is an unsubstituted aromatic group, a substituted aromatic group, a substituted

4. The compound, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is an unsubstituted pyrrolic group, a substituted pyrrolic group, or a substituted

5. The compound, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is an unsubstituted thiophene group, a substituted thiophene group, or a substituted

6. The compound, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is an unsubstituted naphthalenic group, a substituted naphthalenic group, or a substituted

7. The compound, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is a di-substituted phenyl group, a substituted

8. The compound, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein the substituted phenyl urea group of R 3 is a substituted

9. The compound, or a pharmaceutically acceptable salt thereof according to claim 2 , wherein the halide of R 2 is a fluoride or a chloride.

10. The compound, or a pharmaceutically acceptable salt thereof according to claim 2 , wherein the alkyl group of R 2 is a methyl group or an ethyl group.

11. A method of treating a cancer associated with adenosine monophosphate-activated protein kinase, and lipid metabolic disorder or lipid metabolic syndrome, which comprises administering an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

12. The method according to claim 11 , wherein the cancer is liver cancer or breast cancer.

13. The method according to claim 11 , wherein the compound has binding specificity for the alpha subunit of adenosine monophosphate-activated protein kinase and induce phosphorylation of the alpha subunit of adenosine monophosphate-activated protein kinase.

14. The method according to claim 11 , wherein the compound induces apoptosis of adipocytes.

Assignees

• Univ Nat Yang Ming

Inventors

• Shiau Chung-Wai
• Su Jung-Chen
• Lin Yan-Ju
• Huang Jui-Wen

Classifications

• A61P35/00 Primary

  Antineoplastic agents · CPC title

• C07D239/42

  One nitrogen atom (nitro radicals C07D239/30) · CPC title

• C07D401/14

  containing three or more hetero rings · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• C07D409/04

  directly linked by a ring-member-to-ring-member bond · CPC title